Other Briefings
India’s AI Infrastructure and Emerging Market Leadership: An Outlook
India’s artificial intelligence (AI) sector is set to add US$400 billion to the economy by 2030, propelled by favorable policies, rising foreign direct investments (FDI), and surging demand for digital services.
India Mulls Opening Key Government Procurement Market to Foreign Companies
As per media reports published on May 23, 2025, India is considering opening parts of its central government procurement market to foreign firms, including the US.
India’s Passport Rules 2025: Key Changes You Need to Know
India’s 2025 passport reforms introduce biometric ePassport, digital address integration, and stricter documentation rules—enhancing security, streamlining travel, and benefiting global business operations.
BCI’s Revised Rules Expand Scope for Foreign Lawyers in India: What You Need to Know
India’s Bar Council amends 2022 rules to allow foreign lawyers to advise on international and foreign law while maintaining restrictions on Indian law and litigation.
A Guide to Minimum Wage in India in 2025
We answer some frequently asked questions foreign hiring managers may have regarding the minimum wage in India. In April 2025, Delhi revised the monthly minimum wages of all categories of workers in the state, effective April 1, 2025.
FTAs and FDI Fuel Expansion in India’s Luxury Car Segment
India’s luxury car market is expanding rapidly, driven by EV adoption, foreign investment, and trade policy reforms. Explore key trends, FDI data, OEM strategies, and the impact of FTAs shaping the future of the sector.
India’s Manufacturing Sector Poised for Growth Amid Global Trade Shifts: Report
According to a market intelligence report released by S&P Global on May 19, 2025, India’s manufacturing sector is gaining momentum, positioning it as an attractive hub for foreign investors.
Indian Pharma on Alert as US Slashes Drug Prices Under MFN Policy
On May 12, 2025, the Trump administration mandated pharmaceutical companies to reduce the prices of drugs sold in the US under the MFN pricing model. This could affect the Indian pharma sector, a key supplier to the US market.
